Scientific, clinical and pharmaceutical experts together with financial and support specialists all bring together their expertise to path the way to success.

Executive Committee of Cellprothera

Matthieu de KALBERMATTEN

CEO

Read more

20 years of experience in executive management, corporate strategy, business development and sales, for medtech company and large multinationals.

Ibon GARITAONANDIA

CSO

Read more

15 years of experience in stem cell research and regenerative medicine, including Translational Research at a Californian clinical stage biotechnology company developing stem cell-based therapies

Hendrik STREEFKERK

CMO

Read more

Physician with more than 15 years of experience in Academy & Healthcare industry. Translational Medicine and Patient Safety in big pharma and Biotech in Switzerland.

Marc KOWALCZYK

Director Device Development & Industrialisation

Read more

15 years of experience in the design, development and industrialization of medical devices in spine and cardiovascular markets for leading European and American medtech companies.

Olivier FRIEDRICH

CFO

Read more

15 years of experience in corporate finance, internal control, accounting and tax matters. Senior Manager at EY leading legal financial audits as well as due diligence transactions. CFO of a listed company on Euronext

Jean-Olivier HIRSCH

Director Quality
& Regulatory Affairs

Read more

15 years of experience in the pharmaceutical industry, as director of pharmaceutical affairs, head of quality management and qualified person.

Titre

Zone board

Nom

Titre

Lieu

Nom

Titre

Lieu

Nom

Titre

Lieu

Partners

Scientific advisory board

Pr Francis BERENBAUM

APHP

Rheumatologist, MD

INSERM2 Executive committee member

Paris, France

Pr Deepak BHATT

Harvard Medical Business School

Boston MA, USA

Pr Jérôme GUICHEUX

University Hospital

PhD Biology

INSERM Director in Regenerative Medicine

Nantes, France

Pr Christian JORGENSEN

University Hospital

Rheumatologist, MD

INSERM head of research

Montpellier, France

Pr Pierre-Yves MARIE

Universtiy Hospital

Nancy, France

Pr Gilles MONTALESCOT

APHP

Paris, France

Dr Marcus MUMME

UKBB

Orthopedics and Traumatology, MD With special focus on regenerative therapies, Investigator in a phase II cell therapy study

Basel, Switzerland

Pr Guilio POMPILIO

Monzino Cardiology Center

Milano, Italy

Pr Jérôme RONCALLI

Universtiy Hospital

Toulouse, France

Pr Scott SOLOMON

Harvard Medical Business School

Boston MA, USA

Pr Faiez ZANNAD

Universtiy Hospital

Nancy, FrancePr.

Founders

At the origin of the therapeutic solution, Philippe HENON, MD – Head of the Hematology Department, is one of the pioneers in the field of peripheral blood stem cell (PBSC) identification and transplantation and realized the 6th worldwide PBSC graft in 1986… 

Read more

He is member of twelve national and international scientific societies and corresponding member of the New York Academy of Sciences. As the founder of the “Institut de Recherche en Hématologie et Transplantation” (IRHT) in Mulhouse, he led a research program on stemcells and discovered that CD34+ cells could regenerate the heart after a severe myocardial infarct. A pilot trial on 10 patients showed very good results and avoided heart transplantation and iterated hospitalisations to those patients. He is now chairman of the Supervisory Board and Scientific Advisor.

Jean-Claude JELSCH was for over 30 years, an esteemed member of ADECCO top management. After he co-founded Cardinal Development, a capital development company in Alsace, he became Chairman of IRHT.

 

Read more

At the same time when Philippe HENON was leading the pilot study on10 patients. The good results of this Proof of Concept Trial led both Philippe HENON and Jean-Claude JELSCH to found CellProthera in 2008 whose objectives are to develop and bring to patients this innovative therapeutic solution. Philip HENON as President and Scientific Director led the way to set up a research team to develop this innovative therapeutic solution and start the conception of a stemcell purification and expansion device. Whereas Jean-Claude JELSCH as CEO from 2008 to 2016 has consolidated the company by successful fundraisings and led development programs by partnering with industrial companies such as BERTIN TECHNOLOGIES.

Our values